Department of Pharmacy, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China.
Department of Pharmacy, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
J Clin Pharm Ther. 2022 Aug;47(8):1270-1275. doi: 10.1111/jcpt.13671. Epub 2022 Apr 23.
The clinical features of terlipressin-induced ischemic skin necrosis are unknown. The purpose of this study is to explore the clinical features of terlipressin-induced skin necrosis.
We searched Chinese and English databases to collect case reports of terlipressin-induced skin necrosis for retrospective analysis.
A total of 42 patients (31 males and 11 females) from 35 studies were included, with a median age of 54 years (range 0.17-84). The onset of skin ischemia ranged from a few hours to 21 days. The most common clinical manifestations were bulla (15 cases, 35.7%), cyanosis (12 cases, 28.6%), necrosis (11 cases, 26.2%), and purpura (10 cases, 23.8%). The following were often affected: the legs (26 cases), 61.9%), abdomen (13, 31.0%), scrotum (10 cases, 23.8%), feet (10 cases, 23.8%), upper extremities (8 cases, 19.0%), and hands (7 cases, 16.7%). Skin biopsy showed fibrin thrombus (7 cases, 38.9%), nonspecific inflammation (6 cases, 33.3%), and necrosis (10 cases, 55.6%). After discontinuation of terlipressin, skin symptoms improved in most patients.
Ischemic skin necrosis is a rare and serious adverse effect of terlipressin. Patients receiving terlipressin therapy should be monitored closely for terlipressin-related ischemic complications. Terlipressin should be discontinued immediately if ischemic complications occur.
特利加压素引起的缺血性皮肤坏死的临床特征尚不清楚。本研究旨在探讨特利加压素引起皮肤坏死的临床特征。
我们检索了中、英文数据库，收集了特利加压素引起皮肤坏死的病例报告进行回顾性分析。
共纳入 35 项研究中的 42 例患者（31 例男性，11 例女性），中位年龄为 54 岁（范围 0.17-84 岁）。皮肤缺血的发病时间从数小时到 21 天不等。最常见的临床表现为水疱（15 例，35.7%）、发绀（12 例，28.6%）、坏死（11 例，26.2%）和瘀斑（10 例，23.8%）。以下部位常受累：下肢（26 例，61.9%）、腹部（13 例，31.0%）、阴囊（10 例，23.8%）、足部（10 例，23.8%）、上肢（8 例，19.0%）和手部（7 例，16.7%）。皮肤活检显示纤维蛋白血栓（7 例，38.9%）、非特异性炎症（6 例，33.3%）和坏死（10 例，55.6%）。停用特利加压素后，大多数患者皮肤症状改善。
缺血性皮肤坏死是特利加压素的一种罕见且严重的不良反应。接受特利加压素治疗的患者应密切监测特利加压素相关的缺血性并发症。如果发生缺血性并发症，应立即停用特利加压素。
